Seres Therapeutics
MCRB
102 hedge funds and large institutions have $127M invested in Seres Therapeutics in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 42 reducing their positions, and 49 closing their positions.
118% more call options, than puts
Call options by funds: $683K | Put options by funds: $314K
0.69% less ownership
Funds ownership: 4.19% → 3.5% (-0.69%)
24% less funds holding
Funds holding: 134 → 102 (-32)
40% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 42
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less capital invested
Capital invested by funds: $256M → $127M (-$128M)
65% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.05M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.35M |
| 3 |
Millennium Management
New York
|
+$1.89M |
| 4 |
Morgan Stanley
New York
|
+$1.84M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$21.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$6.7M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$5.95M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.33M |
MCRB Hedge Fund Activity: Q4 2023 in Review
102 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2023, worth a combined $127M — down 50% from $256M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of MCRB and 17 opened new positions — a net loss of 32 holders — while 42 trimmed existing stakes and 25 added.
The largest buyer was Hudson Bay Capital Management, adding an estimated $3.05M. The largest seller was Federated Hermes, exiting entirely with an estimated $21.4M sold.
- 102 institutional investors held Seres Therapeutics (MCRB) as of Q4 2023, down from 134 in Q3 2023.
- Funds reported $127M of Seres Therapeutics stock for Q4 2023, down 50% quarter-over-quarter.
- 17 funds opened new Seres Therapeutics positions in Q4 2023 and 49 closed out, a net change of -32 holders.
- The largest Seres Therapeutics buyer in Q4 2023 was Hudson Bay Capital Management, an estimated $3.05M added.
- The largest Seres Therapeutics seller in Q4 2023 was Federated Hermes, an estimated $21.4M sold.
Based on aggregated 13F filings for Q4 2023.